Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 2Solid Tumors 1Leukemia, Myeloid 1Leukemia 1

Interventions

fludarabine phosphate 36Whole-Body Irradiation 30Cyclophosphamide 30Mycophenolic Acid 28Azacitidine 27Tacrolimus 25Peripheral Blood Stem Cell Transplantation 24Busulfan 22Methotrexate 15Cyclosporine 15Antilymphocyte Serum 14Decitabine 11Cytarabine 11Melphalan 10fludarabine 9Radiotherapy 8Filgrastim 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Cord Blood Stem Cell Transplantation 7thymoglobulin 6Sirolimus 6Rituximab 6Cyclosporins 6Clofarabine 6venetoclax 5merphos 5Sorafenib 4Lenalidomide 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelomonocytic, Chronic × glasdegib × Clear all
NCT02367456 2024-01-19

BRIGHT 1012

Pfizer

Phase 1 Completed
73 enrolled 31 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04842604 2023-12-18

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Pfizer

Phase 3 Completed
14 enrolled 11 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01842646 2021-06-14

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
35 enrolled 7 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡